Public Companies
Cybin Inc. Announces Virtual R&D Day
Cybin (NEO: CYBN | NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D…
Cybin (NEO: CYBN | NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for the treatment of major depressive disorder, and CYB004, which is being evaluated for the treatment of generalized anxiety disorder. According to the announcement, the event will feature an interim readout from CYBN’s ongoing phase 1/2a study evaluating CYB003 as well as an update from the ongoing phase 1 exploratory CYB004-E trial evaluating IV N,N-dimethyltryptamine; the event will also include a review of CYBN’s clinical development program evaluating CYB004.
To view the live webcast, visit https://ibn.fm/TDgqt
To view the full press release, visit https://ibn.fm/3dzip
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
-
Psilocybin1 week ago
Tulum vs. Oaxaca: The Tale of 2 Psychedelic Cities
-
Psychedelics6 days ago
Exploring Psilocybin’s Potential in Diabetes Management
-
Psychedelics6 days ago
All About the New Ketamine Trial at the University of Otago
-
Psychedelics1 week ago
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
Law & Regulation1 week ago
Canada’s Optimi Health to ship psilocybin to New Zealand psychedelics research center
-
Psychedelics6 days ago
The EU’s Plan for a €6.5M Study of Psychedelics To Treat Mental Disorders
-
Psychedelics1 week ago
Missouri Considers $10 Million from Opioid Settlements for Psilocybin Research
-
Law & Regulation1 week ago
Synaptogenix increases psilocybin stake with PsygaBio